Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Therapeutics Announces Vaccine Development Suppliers In Europe
34 companies found
based inBasel, SWITZERLAND
We at Auris Medical are a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. We are focusing on the development of intranasal betahistine ...
based inEgna, ITALY
We are a young and innovative company that has successfully specialized in the branch of physiotherapy medicine, rehabilitation and aesthetics. Our successfully tested systems offer a guarantee of quality and reliability for customers. Our company ...
based inMunich, GERMANY
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic ...
based inVienna, AUSTRIA
Aposcience AG is a worldwide innovation leader in the field of regenerative medicine. Regenerative medicine has the potential to transform the treatment for diseases with high medical need, as the tissues afflicted by the disease process can be ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...
based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging is a clinical phase biotechnology company focused on enabling image guided interventional medicine. The company´s molecular targetting technology has the potential to tackle disease in real-time to allow interventional ...
based inDijon, FRANCE
At Exeliom Biosciences, we develop novel therapeutic approaches to unleash the therapeutic potential of key players in the Microbiome - Host interactions to fight immune-mediated diseases, starting with inflammatory bowel diseases. There is a time ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inLondon, UNITED KINGDOM
Multiomic Health Limited is a next-generation precision medicine business, applying computational systems biology to develop and commercialize data assets for metabolic syndrome. Multiomic is a next-generation precision medicine business, applying ...
based inSchlieren, SWITZERLAND
Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome. PharmaBiome has developed ...
based inOverath, GERMANY
Spiggle & Theis Medizintechnik GmbH was founded as a family-owned company in 1994 in Dieburg near Darmstadt. Since then, SPIGGLE & THEIS has been developing and distributing its products in over 75 countries worldwide. By keeping an eye on the ...
based inWendelsheim, GERMANY
MODAG aims to provide a novel approach for treating neurodegenerative diseases by combining targeted small molecule therapeutics with the right diagnostic tools. Our first objective is to demonstrate clinical proof-of-concept with our lead compound ...
based inBerlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
based inOxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
based inMunich, GERMANY
multimmune GmbH is a private, clinical-stage biopharmaceutical company which has developed a unique and proprietary technology platform for the development and clinical delivery of new cancer therapies on the basis of the founding scientists' ...
based inKleinostheim, GERMANY
SCHWIND eye-tech-solutions is one of the technology leaders for eye lasers for refractive and therapeutic corneal surgery. We develop, produce and market a comprehensive product portfolio for the treatment of vision defects and corneal diseases. ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inGravesano, SWITZERLAND
AD SWISS MEDTECH SA is a Swiss medical company that develops innovative technologies for rehabilitation medical devices. We are specialized in the development of non-invasive technologies with high therapeutic impact value. Our commitment is to ...
